iBio Announces First Agreement for Fill-Finish Services


iBio, Inc. recently announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies.

Earlier in June, iBio introduced its new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics. Focused initially on clients with preclinical and clinical stage programs, iBio’s fill-finish operation is housed in the company’s 135,000-sq-ft CDMO facility located in Bryan, TX.

Pursuant to the supply agreement, iBio will formulate and fill clinical research quantities of one of the customer’s investigational therapies into sterile vials for use in a planned late-stage clinical trial. The customer’s identity will be disclosed at the time and in the manner consistent with the customer’s own disclosure practices.

“Shortly after our fill-finish services launch at BIO 2019, this first supply agreement with an emerging leader in the gene and cell therapy space was established. While we expect our new fill-finish capabilities will also be attractive to our end-to-end CDMO services clients, this first agreement was secured as a stand-alone project and helps validate our ability to work with a variety of cell-based and other biopharmaceutical products in different formats,” said Robert B. Kay, iBio’s Chairman and CEO.

iBio is a global leader in plant-based biopharmaceutical contract development and manufacturing services. With iBio’s FastPharming protein expression and glycan engineering technologies, consistently high-quality biologics can be produced rapidly in plants using automated hydroponic systems at iBio CDMO, LLC in Bryan, TX. In addition to cGMP contract manufacturing, iBio also offers process development, bioanalytical, and fill-finish services, along with factory solutions for the design and build of facilities for plant-made biopharmaceuticals. For more information, visit www.ibioinc.com.

Share This